Respiratory Syncytial Virus (RSV)
Conditions
Brief summary
The purpose of this study is to evaluate the immunogenicty and safety of an RSV-F protein nanoparticle vaccine, with out without aluminum, in healthy women of child-bearing potential.
Interventions
BIOLOGICALLow dose RSV-F Vaccine with Adjuvant
0.5mL IM Injection
BIOLOGICALLow dose RSV-F Vaccine without Adjuvant
0.5ml IM Injection
BIOLOGICALHigh dose RSV-F Vaccine with Adjuvant
0.5mL IM Injection
BIOLOGICALHigh dose RSV-F Vaccine without Adjuvant
0.5mL IM Injection
BIOLOGICALLow dose RSV-F Vaccine with Adjuvant [Bedside Mixing]
0.5mL IM Injection
BIOLOGICALPlacebo
0.5mL IM Injection
Sponsors
Novavax
PATH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult females, ≥ 18 and ≤ 35 years of age. Healthy shall be defined by the absence of any illness, acute or chronic, that requires ongoing systemic therapy for the control of symptoms or prevention of disability. * Subjects on stable (no change in ≥ 3 months) therapy for findings (e.g., hypertension or hyperlipidemia) that are not associated with symptoms or disability are eligible, as are users of hormonal contraceptives. * Subjects who receive intermittent prophylaxis for risks associated with asymptomatic findings (e.g., antibiotic prophylaxis prior to dental procedures in a subject with mitral valve prolapse) are eligible. * Ongoing therapy will be defined as continuous or, if intermittent, more frequent than once every 3 months (e.g., use of an inhaled bronchodilator for exercise-induced bronchospasm more than once every 3 months). Immunosuppressives are subject to exclusion criterion #5 below. * Persons being treated for illnesses or conditions that would become acutely symptomatic or disabling in the absence of treatment are not eligible. * Willing and able to give informed consent prior to study enrollment. * Able to comply with study requirements. * Women who are not surgically sterile must have a negative urine pregnancy test prior to each vaccination; will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of continuous abstinence from heterosexual activity, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and IUD.
Exclusion criteria
* Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first vaccination. * History of a serious reaction to any prior vaccination. * Received any vaccine in the 4 weeks preceding the study vaccination; or any RSV vaccine at any time. * Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination. * Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted. * Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study. * Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature \>38.0°C on the planned day of vaccine administration). * Known disturbance of coagulation. * Women who are pregnant or breastfeeding, or plan to become pregnant during the study. * Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse. * Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the safety | Day 0 to Day 182 | Number (and percentage) of subjects with solicited local and systemic Adverse Events over the seven days post-injections; all adverse events, solicited and unsolicited over 56 days post-first injection. Significant New Medical Conditions, Medically Attended Events and Serious Adverse Events will be collected for six months |
| Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen across treatment groups | Day 0 to Day 112 | Immunogenicity will be measured using derived / calculated endpoints based on: * Geometric mean titer (GMT) * Geometric mean ratio (GMR) * Seroconversion rate (SCR) * Seroresponse rate (SRR) |
Secondary
| Measure | Time frame |
|---|---|
| Immunogenicity based on neturalizing antibody titer | Day 0 to Day 112 |
Countries
United States
Outcome results
None listed